Abstract: The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5:1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.

Abstract: The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5:1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.

Abstract: The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5:1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.

Abstract: The invention provides compounds of Formula I: wherein b, D, R1, R2, G, Ra and Rb have meanings given in the description, or pharmaceutically-acceptable salts or solvates, or pharmaceutically functional derivatives thereof. The invention further provides process for conjugating the compounds to carrier molecules and uses of such compounds and conjugates in the treatment of disease.

Abstract: The invention provides a compound comprising a photosensitizing agent coupled to a carrier molecule with a minimum coupling ratio of 3:1 wherein the carrier molecule has a binding specificity for a target cell. There is also provided a process of conjugation comprising the use of a first and second aprotic solvent and uses of the conjugated compounds.

Abstract: The invention provides compounds of Formula (I): wherein b, D, R1, R2, G, Ra and Rb have meanings given in the description, or pharmaceutically-acceptable salts or solvates, or pharmaceutically functional derivatives thereof. The invention further provides process for conjugating the compounds to carrier molecules and uses of such compounds and conjugates in the treatment of disease.

Abstract: FR1 ?????????1?????????2?????????3 H1-H2 Locus 123456789012345678901234567890 VH1 1-3 1-02 QVQLVQSGAEVKKPGASVKVSCKASGYTFT 1-3 1-03 QVQLVQSGAEVKKPGASVKVSCKASGYTFT 1-3 1-08 QVQLVQSGAEVKKPGASVKVSCKASGYTFT 1-2 1-18 QVQLVQSGAEVKKPGASVKVSCKASGYTFT 1-U 1-24 QVQLVQSGAEVKKPGASVKVSCKVSGYTLT 1-3 1-45 QMQLVQSGAEVKKTGSSVKVSCKASGYTFT 1-3 1-46 QVQLVQSGAEVKKPGASVKVSCKASGYTFT 1-3 1-58 QMQLVQSGPEVKKPGTSVKVSCKASGFTFT 1-2 1-69 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS 1-2 1-e QVQLVQSGAEVKKPGSSVKVSCKASGGTFS 1-2 1-f EVQLVQSGAEVKKPGATVKISCKVSGYTFT VH2 3-1/2-1 2-05 QITLKESGPTLVKPTQTLTLTCTFSGFSLS 3-1 2-26 QVTLKESGPVLVKPTETLTLTCTVSGFSLS 3-1 2-70 QVTLKESGPALVKPTQTLTLTCTFSCFSLS VH3 1-3 3-07 EVQLVESGGGLVQPGGSLRLSCAASGFTFS 1-3 3-09 EVQLVESGGGLVQPGRSLRLSCAASGFTFD 1-3 3-11 QVQLVESGGGLVKPGGSLRLSCAASGFTFS 1-1 3-13 EVQLVESGGSLVQPGGSLRLSCAASGFTFS 1-U 3-15 EVQLVESGGGLVKPGGSLRLSCAASGFT

Abstract: The present invention relates to a compound of formula (I): Formula (I) wherein one or two of A, B, C and D are each independently selected from S, O, Se and Te, and the remainder are N; a, b, c and d are each independently substituted or unsubstituted 5-membered heterocyclic groups having the members necessary to complete a porphyrin, chlorin, bacteriochlorin or isobacteriochlorin nucleus in which one or two of the nitrogens are replaced by S, O, Se or Te; M is H or a metal; R1, R2, R3 and R4 are each independently selected from: H; alkyl; cycloalkyl; halogen; aryl or heteroaryl, each of which may be optionally substituted by one or more substituents selected from OH, CN, CF3, alkyl, alkoxy, haloalkyl, halogen, an isothiocyanate group, a haloacetamide, maleimide, NH2, NO2, CONH2, COOH, COO-alkyl, —OZ, —COOZ, a polyethylene glycol group, an alkyl sulfonate group, an alkyl-COOH group, a substituted or unsubstituted benzyl group, a sugar derivative, —C?C—(CH2)pCO2R10, where R10 is H or alkyl, and O(CH2)rCOR11,

Abstract: A compound of formula I is disclosed: wherein each R1 is independently wherein W is an aryl, alkyl or heteroaryl group, each of which may be independently and optionally substituted by one or more of: OH, halogen, an isothiocyanate group, a haloacetamide, maleimide, COOH, NO2, NH2, alkyl, haloalkyl, alkoxy, (CO)n(O)mZ, a polyethylene glycol group, an alkyl sulfonate group, an alkyl-COOH group, a substituted or unsubstituted benzyl group, or a sugar derivative; R2 is H, a halogen, an isothiocyanate group, a haloacetamide, maleimide, Y-aryl or Y-heteroaryl, where Y is O, S, NH, C(O) or CO2, and where said aryl or heteroaryl group may be optionally substituted by one or more of: OH, halogen, an isothiocyanate group, a haloacetamide, maleimide, COOH, NO2, NH2, alkyl, haloalkyl, alkoxy, (CO)n?(O)m?Z?, a polyethylene glycol group, an alkyl sulfonate group, an alkyl-COOH group, a substituted or unsubstituted benzyl group, or a sugar derivative; Z and Z? are each independently silicon-containing protecti